179552-75-1

Basic information

• Product Name: N-(3-chloro-4-fluorophenyl)-7-Methoxy-6-aminoquinazolin-4-aMine
• Synonyms: N-(3-chloro-4-fluorophenyl)-7-Methoxy-6-aminoquinazolin-4-aMine;N4-(3-Chloro-4-fluorophenyl)-7-methoxyquinazoline-4,6-diamine
• CAS NO: 179552-75-1
• Molecular Formula: C₁₅H₁₂ClFN₄O
• Molecular Weight: 318.7333832
• EINECS: -0
• Mol File: 179552-75-1.mol
• Article Data: 26

Chemical Properties

• Boiling Point: 487.3±45.0 °C(Predicted)
• Appearance: /
• Density: 1.458±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 6.03±0.30(Predicted)
• CAS DataBase Reference: N-(3-chloro-4-fluorophenyl)-7-Methoxy-6-aminoquinazolin-4-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-chloro-4-fluorophenyl)-7-Methoxy-6-aminoquinazolin-4-aMine(179552-75-1)
• EPA Substance Registry System: N-(3-chloro-4-fluorophenyl)-7-Methoxy-6-aminoquinazolin-4-aMine(179552-75-1)

Safety Data

• Hazardous Substances Data: 179552-75-1(Hazardous Substances Data)

Usage

General Description

N-(3-chloro-4-fluorophenyl)-7-Methoxy-6-aminoquinazolin-4-aMine is a chemical compound with potential pharmaceutical applications. It is a quinazoline derivative, containing a chlorine and fluorine substituted phenyl ring, along with a methoxy group and an amino group attached to the quinazoline core. N-(3-chloro-4-fluorophenyl)-7-Methoxy-6-aminoquinazolin-4-aMine may exhibit biological activities such as kinase inhibition or anti-cancer properties, due to its structural features and potential interactions with cellular targets. Further research and development are needed to fully understand the pharmacological properties and potential therapeutic uses of N-(3-chloro-4-fluorophenyl)-7-Methoxy-6-aminoquinazolin-4-aMine.

Upstream product

• 179552-74-0 N-(3-chloro-4-fluorophenyl)-7-methoxy-6-nitroquinazolin- 4-amine 
• 367-21-5 3-chloro-4-fluorophenylamine 
• 162012-69-3 7-fluoro-6-nitro-4-hydroxyquinazoline 
• 53449-14-2 7-chloro-6-nitro-4(3H)-quinazolinone 
• 89-77-0 2-Amino-4-chlorobenzoic acid 
• 31374-18-2 7-chloro-3,4-dihydroquinazolin-4-one 
• 1012057-47-4 7-methoxy-6-nitroquinazolin-4(3H)-one 
• 55496-69-0 4-chloro-7-methoxy-6-nitroquinazoline 
• 16499-57-3 7-fluoro-3H-quinazolin-4-one 
• 446-32-2 4-fluoroanthranilic acid 
• 162012-70-6 4-chloro-7-fluoro-6-nitroquinazoline 
• 162012-69-3 7-fluoro-6-nitro-3H-quinazolin-4-one 
• 162012-67-1 N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine 
• 1012057-48-5 N-(3-chloro-4-fluorophenyl)-7-methoxy-6-nitroquinazolin-4-amine hydrochloride 

Downstream Products

• 1012057-49-6 methyl 3-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-ylcarbamoyl)butanoate 
• 1012920-25-0 C₁₅H₁₀ClFIN₃O 
• 1414884-63-1 (E)-N-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]-4-[2-azaspiro[ 3.4]octan-2-yl]-2-butenamide 
• 1012054-73-7 N₁-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)-N₅-hydroxyglutaramide 
• 1110813-31-4 Dacomitinib 

Relevant articles and documents

Industrial Cunninghamia lanceolata carbon supported FeO(OH) nanoparticles-catalyzed hydrogenation of nitroarenes

The development of green and efficient methods for hydrogenation of nitroarenes is still highly demanding in organic synthesis. Herein, we report an industrial Cunninghamia lanceolata carbon supported FeO(OH) nanoparticles process for the synthesis of aryl amines with good yields via hydrogenation of nitroarenes. Nine key anti-cancer drug intermediates were successfully achieved with protocol. And Osimertinib intermediate 4m can be smoothly synthesized at a 2.67 kg-scale with >99.5% HPLC purity. This protocol features cheap carbon source, highly catalytic activity, simple operation, kilogram-scalable and recyclable catalysts (eight times without observable losing activity).

Tyrosine kinase inhibitor and pharmaceutical application thereof

The invention relates to a tyrosine kinase inhibitor containing a quinazoline derivative in the fields of tumor treatment medicines and the like, and application of the tyrosine kinase inhibitor in treatment medicines for inhibiting and treating diseases caused by overexpression of tyrosine kinase. The active ingredient of the tyrosine kinase inhibitor is a quinazoline derivative with a structure shown in the following formula: a functional group containing XCH2 (CH2) nC = O is introduced on the basis of a quinazoline structure, and the functional group is easily combined with cysteine sulfydryl through nucleophilic reaction to form a covalent bond so that the activity of tyrosine kinase is irreversibly inhibited.

STEFs: Activated Vinylogous Protein-Reactive Electrophiles

Reported here is the synthesis of a class of semi-oxamide vinylogous thioesters, designated STEFs, and the use of these agents as new electrophilic warheads. This work includes preparation of simple probes that contain this reactive motif as well as its installation on a more complex kinase inhibitor scaffold. A key aspect of STEFs is their reactivity towards both thiol and amine groups. Shown here is that amine conjugations in peptidic and proteinogenic samples can be facilitated by initial, fast conjugation to proximal thiol residues. Evidence that both the selectivity and the reactivity can be tuned by the structure of STEFs is provided, and given the unique ability of this functionality to conjugate by an addition-elimination mechanism, STEFs are electrophilic warheads that could find broad use in chemical biology.